# US 2012/0251446 A1 · Peptide Conjugates Comprising Polyhistidine Sequence and Free Cysteine and Their Uses in Imaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251446 A1
- Document ID: US20120251446A1
- Status: Published application
- Kind: A1
- Application number: 13/390,673
- Filed: 2010-08-18
- Published: 2012-10-04
- Earliest claimed: 2009-08-18
- Assignees: King's College London
- Inventors: Richard Tavare; Gregory Mullen; Philip Blower; Rafael Torres Martin de Rosales; Jennifer Williams
- Web page: https://patentgrep.com/patent/US20120251446A1

## CPC

- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 51/048: {DTPA (diethylenetriamine tetraacetic acid)}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Bioconjugates for use in imaging are disclosed include a linker sequence fused to a polypeptide capable of binding a target in a biological system. The linker sequence is designed so that it is capable of being radiolabelled, e.g. with a complex comprising a radionuclide, via a free cysteine residue and the polyhistidine sequence in the label that are both capable of simultaneously binding to a complex comprising the radionuclide. These interactions can improve significantly the rate and efficiency of radiolabelling compared to either protein with the His-tag or the free cysteine alone. Optionally, the free cysteine residue provides a site which can be covalently bonded to a moiety such as a second label, in a site-specific manner.

## Claims

### Claim 1

A bioconjugate for use in imaging that comprises:
a polypeptide which is capable of interacting with a target of interest in a biological system; and
a linker sequence covalently bonded to the polypeptide, the linker sequence comprising (a) a free cysteine residue and (b) a polyhistidine sequence which is capable of site-specific labelling with a radionuclide for imaging the target of interest using the bioconjugate;
wherein both the free cysteine residue and the polyhistidine sequence are capable of simultaneously interacting with the radionuclide.

### Claim 2 (depends on 1)

The bioconjugate of claim 1, wherein free cysteine and the polyhistidine sequences bind to a complex comprising the radionuclide.

### Claim 3 (depends on 1)

The bioconjugate of claim 1, further comprising a complex comprising a radionuclide bound to the free cysteine residue and to the polyhistidine sequence.

### Claim 4 (depends on 1)

The bioconjugate of claim 1, wherein the free cysteine residue is separated from the polyhistidine sequence by 5 to 10 amino acid residues.

### Claim 5 (depends on 1)

The bioconjugate of claim 1, wherein the polyhistidine sequence has between 5 and 10 histidine residues.

### Claim 6 (depends on 5)

The bioconjugate of claim 5, wherein the polyhistidine sequence has 5, 6 or 10 histidine residues.

### Claim 7 (depends on 1)

The bioconjugate of claim 1, wherein the linker sequence is fused to the C-terminus of the protein domain.

### Claim 8 (depends on 1)

The bioconjugate of claim 1, wherein linker sequence is represented by the general formula -Cys-Xn-His5-10, where X is any amino acid residue and n is between 5 and 10.

### Claim 9 (depends on 1)

The bioconjugate of claim 1, wherein the polypeptide is a protein domain or an antibody, or a fragment thereof.

### Claim 10 (depends on 9)

The bioconjugate of claim 9, wherein the protein domain is a C2 domain of a phosphatidylserine binding protein.

### Claim 11 (depends on 9)

The bioconjugate of claim 9, wherein the polypeptide is selected from the group consisting of, C2A domain of synaptotagmin I, an anti-CD33 antibody, TIMP-2, complement receptor 2 (CR2), an anti-CD169 antibody, an anti-CD68 antibody, an anti-CD64 antibody, and domains or fragments thereof.

### Claim 12 (depends on 2)

The bioconjugate of claim 2, wherein the radionuclide is selected from the group consisting of isotopes of technetium, rhenium, copper, cobalt, gallium and indium.

### Claim 13 (depends on 12)

The bioconjugate of claim 12, wherein the radionuclide is selected from the group consisting of Tc-99m, Re-186, Re-188, Co-57, Ga-67, In-111, Cu-64, Cu-60, Cu-61, Cu-62, Cu-67, Tc-94m, Ga-68 and Co-55.

### Claim 14 (depends on 1)

The bioconjugate of claim 1, wherein the free cysteine is capable of site-specific linkage to a label.

### Claim 15 (depends on 14)

The bioconjugate of claim 14, wherein the label is covalently linked to the linker sequence by a reaction with the free cysteine residue.

### Claim 16 (depends on 14)

The bioconjugate of claim 14, wherein the free cysteine is covalently bonded to the label via a sulfhydryl-reactive maleimide, haloacetyl, pyridyldisulfide or vinyl sulfone group of the label reacting with the free thiol group of the cysteine residue.

### Claim 17 (depends on 14)

The bioconjugate of a claim 14, wherein the label covalently bonded to is selected from the group consisting of a fluorescent label, a MRI contrast agent, a small molecule drug and a toxin.

### Claim 18 (depends on 1)

The bioconjugate of claim 1, wherein the linker is expressed as a fusion with the polypeptide.

### Claim 19

A kit for making a labelled bioconjugate for use in imaging employing a polypeptide which is capable of interacting with a target of interest in a biological system, the kit comprising:
(i) a linker sequence for covalently linking to the polypeptide, the linker sequence comprising (a) a free cysteine residue and (b) a polyhistidine sequence which is capable of site-specific labelling with a radionuclide for imaging the target of interest using the bioconjugate, wherein both the free cysteine residue and the polyhistidine sequence are capable of simultaneously interacting with the radionuclide, or a nucleic acid sequence encoding the linker sequence for ligation to a nucleic acid sequence encoding the polypeptide;
(ii) optionally, a reagent comprising the radionuclide for labelling the polyhistidine sequence;
(iii) optionally, a label for site-specific reaction with the free cysteine residue of the linker; and
(iv) optionally, one or more additional reagents for carrying out the radiolabelling or labelling reactions.

### Claim 20

(canceled)

### Claim 21

A method of making a bioconjugate for use in imaging, the method comprising:
(i) expressing a fusion protein of a polypeptide which is capable of interacting with a target of interest in a biological system and a linker sequence comprising (a) a free cysteine residue, wherein both the free cysteine residue and the polyhistidine sequence are capable of simultaneously interacting with the radionuclide, and (b) a polyhistidine sequence which is capable of site-specific labelling with a radionuclide for imaging the target of interest using the bioconjugate;
(ii) contacting the fusion protein with a complex comprising the radionuclide so that the complex binds to the polyhistidine sequence;
(iii) optionally reacting the free cysteine residue and the label so that the label covalently bonds to cysteine residue.

### Claim 22

A method of imaging employing a bioconjugate that comprises:
a polypeptide which is capable of interacting with a target of interest in a biological system; and
a linker sequence covalently bonded to the polypeptide, the linker sequence comprising (a) a free cysteine residue and (b) a polyhistidine sequence which is capable of site-specific labelling with a radionuclide for imaging the target of interest using the bioconjugate, wherein both the free cysteine residue and the polyhistidine sequence are capable of simultaneously interacting with the radionuclide;
said method comprising the steps of:
(i) introducing the bioconjugate into the biological system comprising the target of interest.
(ii) detecting the radionuclide to image the target of interest in the biological system; and
(iii) optionally detecting the label.

### Claim 23 (depends on 22)

The bioconjugate for use in a method of imaging of claim 22, wherein the method images cell death.

### Claim 24 (depends on 22)

The bioconjugate for use in a method of imaging of claim 22, wherein the imaging is in vivo imaging.

### Claim 25 (depends on 22)

The method of imaging of claim 22, wherein the method detects apoptosis.

### Claim 26 (depends on 23)

The method of imaging of claim 23, wherein the imaging of cell death is for an oncological, cardiovascular or graft rejection application.

### Claim 27 (depends on 22)

The method of imaging of claim 22, wherein the radionuclide is detected by SPECT or PET.

### Claim 28 (depends on 22)

The method of imaging of claim 22, wherein the radionuclide and label are detected in a multi-modal imaging method.

### Claim 29

(canceled)
